Mechanism of potentiation of tissue-type plasminogen activator

被引:0
|
作者
Lazos, SA [1 ]
Wong, SS [1 ]
机构
[1] UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL & LAB MED,HOUSTON,TX 77030
来源
BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL | 1995年 / 37卷 / 06期
关键词
tissue-type plasminogen activator; fibrinogen; plasminogen; fibrin; fibrin fragments; synthetic peptide;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The conversion of plasminogen to plasmin catalyzed by tissue-type plasminogen activator is accelerated in the presence of fibrin, leading to an increased dissolution of fibrin clots. This rate enhancement is mimicked by a dodecapeptide segment of the fibrin molecule containing the sequence A alpha 149-160 (RLEVDIDIKIRS). At low concentrations of the dodecapeptide, the potentiation increases with concentration, but at high concentrations, the stimulation effect diminishes, giving rise to a bell-shaped curve. The maximum rate enhancement of about 10 fold is achieved at a concentration of 85 mu g/mL. This concentration dependent phenomenon is also observed for two synthetic peptide analogues, GLEVDIDIKIRS and RGGGGGGGKIRS, although the acceleration potential is less. These results indicate that the N-terminal amino acids are not critical for the rate enhancement. The bell-shaped activity-concentration curve suggests that the dodecapeptide may bind to both plasminogen and t-PA. This speculation is further supported by the modification of the potentiator. When the A alpha 149-160 dodecapeptide is pretreated with trypsin or phenyl glyoxal, the potentiation activity is eliminated. We speculate that the acceleration of the plasminogen-to-plasmin reaction catalyzed by t-PA is achieved through the action of the stimulator to bring the enzyme and its substrate together as a bi-dentate cross-linker. This effect increases the apparent concentration of the substrate at the enzyme active site, and is reflected as a decrease in Michaelis-Menten constant.
引用
收藏
页码:1071 / 1077
页数:7
相关论文
共 50 条
  • [21] Tissue-type plasminogen activator as a therapeutic target in stroke
    Gravanis, Iordanis
    Tsirka, Stella E.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (02) : 159 - 170
  • [22] New Pathway for Tissue-Type Plasminogen Activator Regulation
    Chasman, Daniel I.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34 (05) : 964 - 965
  • [23] LAMININ INTERACTS WITH PLASMINOGEN AND ITS TISSUE-TYPE ACTIVATOR
    SALONEN, EM
    ZITTING, A
    VAHERI, A
    FEBS LETTERS, 1984, 172 (01) : 29 - 32
  • [24] HETEROGENEITY OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    OPDENAKKER, G
    BOSMAN, F
    DECOCK, B
    CABEZAARVELAIZ, Y
    VANDAMME, J
    BILLIAU, A
    FEBS LETTERS, 1988, 238 (01) : 129 - 134
  • [25] INHIBITION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY PENICILLINS
    HIGAZI, A
    MEYER, M
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1988, 26 (06): : 380 - 380
  • [26] CORONARY THROMBOLYSIS WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    ROBBINS, G
    NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (23): : 1534 - 1535
  • [27] An endothelial storage granule for tissue-type plasminogen activator
    Emeis, JJ
    vandenEijndenSchrauwen, Y
    vandenHoogen, CM
    dePriester, W
    Westmuckett, A
    Lupu, F
    JOURNAL OF CELL BIOLOGY, 1997, 139 (01): : 245 - 256
  • [28] ORIGINS OF THE SPECIFICITY OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    DING, L
    COOMBS, G
    STRANDBERG, L
    NAVRE, M
    COREY, D
    MADISON, E
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1134 - 1134
  • [29] Tissue-type plasminogen activator deficiency exacerbates arthritis
    Yang, YH
    Carmeliet, P
    Hamilton, JA
    JOURNAL OF IMMUNOLOGY, 2001, 167 (02): : 1047 - 1052
  • [30] The End of Tissue-Type Plasminogen Activator's Reign?
    Derraz, Imad
    STROKE, 2022, 53 (08) : 2683 - 2694